We compared pre-amplification (PA) RT-PCR blood CD19 mRNA quantification with flow cytometry (FC), to personalize rituximab re-treatment in neuromyelitis optica spectrum disorders (NMOSDs) patients. 47 blood samples from 3 NMOSDs patients were studied. PA-RT-PCR quantified CD19 in all samples, and a positivity threshold was defined, whereas CD19. + B cells were under threshold in 31/47 samples by FC. In all samples where CD19. + B cells were above FC threshold, they resulted above the PA-RT-PCR threshold. CD19 mRNA was above threshold in 8 other samples, resulted negative by FC, and preceded the FC positivity in 7/8 samples by 1-3. months, showing major sensitivity.
CD19 mRNA quantification improves rituximab treatment-to-target approach: A proof of concept study
Marnetto F.
First
;Valentino P.;
2014-01-01
Abstract
We compared pre-amplification (PA) RT-PCR blood CD19 mRNA quantification with flow cytometry (FC), to personalize rituximab re-treatment in neuromyelitis optica spectrum disorders (NMOSDs) patients. 47 blood samples from 3 NMOSDs patients were studied. PA-RT-PCR quantified CD19 in all samples, and a positivity threshold was defined, whereas CD19. + B cells were under threshold in 31/47 samples by FC. In all samples where CD19. + B cells were above FC threshold, they resulted above the PA-RT-PCR threshold. CD19 mRNA was above threshold in 8 other samples, resulted negative by FC, and preceded the FC positivity in 7/8 samples by 1-3. months, showing major sensitivity.
| File | Dimensione | Formato | |
|---|---|---|---|
|
1-s2.0-S0165572814008856-main.pdf
Accesso aperto
Tipo di file:
PDF EDITORIALE
Dimensione
780.89 kB
Formato
Adobe PDF
|
780.89 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
